Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Renal and urinary disorders – page 13

  • 580 clinical trials
  • 226 recruiting
  • 296 conditions
  • 27 countries

Conditions in this area

296 conditions with trials, the busiest first

Chronic kidney disease61Bladder cancer54Transitional cell carcinoma46Renal cell carcinoma42Bladder transitional cell carcinoma33IgA nephropathy23Acute kidney injury21Non-small cell lung cancer19Lupus nephritis18Clear cell renal cell carcinoma17Urinary tract infection17Paroxysmal nocturnal haemoglobinuria16Breast cancer14Metastatic renal cell carcinoma14End stage renal disease13Congenital cystic kidney disease12Colorectal cancer11Endometrial cancer11Hepatocellular carcinoma11Malignant melanoma11Nephrotic syndrome11Ovarian cancer11Glomerulonephritis membranous10Kidney transplant rejection10+272

Clinical trials in Renal and urinary disorders

580 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

580 clinical trials

Hyperkalaemia+1

Recruiting

Study of sodium zirconium cyclosilicate compared to standard care for managing high blood potassium levels in patients with chronic kidney disease

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Zirconium Cyclosilicate
  • Sponsor:Instituto De Investigacion Sanitaria Fundacion Para La Investigacion Del Hospital Clinico De Valencia-INCLIVA

Type 2 diabetes mellitus+1

Recruiting

Study on the Effects of Finerenone and SGLT2 Inhibitors on Heart and Kidney Health in Patients with Type 2 Diabetes and Chronic Kidney Disease

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Region Midtjylland

Chronic kidney disease

Recruiting

Study on the Effects of Dapagliflozin on Kidney Health in Patients with Chronic Kidney Disease After Kidney Transplantation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Universitaetsklinikum Erlangen AöR

Bladder cancer

Recruiting

Study comparing BCG and combination of BCG with electromotive mitomycin-C treatment in patients with high-risk non-muscle-invasive bladder cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Mitomycin
  • Sponsor:Turku University Hospital

Foetal exposure during pregnancy+2

Recruiting

Study of Metformin to Extend Pregnancy Duration in Women with Preterm Preeclampsia

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Metformin Hydrochloride
  • Sponsor:Amsterdam UMC Stichting

Renal failure

Recruiting

Study on Everolimus for Preventing Rejection in Adult Kidney Transplant Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Hospices Civils De Lyon

Urethral valves

Recruiting

Study on Early Oxybutynin Treatment for Boys with Posterior Urethral Valves

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Oxybutynin
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Haemolytic uraemic syndrome

Recruiting

Study on the Effectiveness of INM004 for Children with Hemolytic Uremic Syndrome Caused by Shiga Toxin-Producing E. coli

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Equine Immunoglobulin F(Ab')2 Fragments Targeting Shiga Toxin
  • Sponsor:Chemo Research S.L.

Bladder cancer

Recruiting

Study on the Effectiveness of Gemcitabine Hydrochloride for Patients with Low Grade Bladder Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine Hydrochloride
  • Sponsor:Medical University Of Vienna

Renal failure+1

Recruiting

Study on Optimal Dose of Rabbit Anti-Human T-Lymphocyte Immunoglobulin and Mycophenolic Acid for Kidney Transplant Patients with Low Immunological Risk

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Mycophenolic Acid
  • Sponsor:Centre Hospitalier Regional Universitaire

Nephrotic syndrome

Recruiting

Study on Obinutuzumab vs. Rituximab for Children with Steroid-Dependent and Frequent Relapsing Nephrotic Syndrome

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Obinutuzumab
  • Sponsor:Assistance Publique Hopitaux De Paris

End stage renal disease+1

Recruiting

Study on Alkaline Phosphatase for Reducing Kidney Transplant Complications in Patients with End-Stage Kidney Disease

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Alkaline Phosphatase, Bovine
  • Sponsor:Amsterdam UMC Stichting

Substances studied in this area

The therapies tested most often in Renal and urinary disorders trials.

Pembrolizumab52 clinical trialsNivolumab36 clinical trialsMycophenolate Mofetil24 clinical trialsDapagliflozin23 clinical trialsCabozantinib22 clinical trialsCisplatin22 clinical trialsIpilimumab21 clinical trialsGemcitabine20 clinical trialsSodium Chloride17 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.